Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA)

Phase 4

Withdrawn

• Conditions: Hypertension
• Interventions: Drug: Eplerenone 50mg; Drug: Placebo

• Registration Number: NCT04746495
• Lead Sponsor: University of Michigan

Brief Summary

This blinded cross-over clinical trial will enroll participants with mild stage 1 hypertension to evaluate whether urinary extracellular transcript abundance predicts response to an mineralocorticoid receptor (MR) antagonist, eplerenone.

Eligible participants will have a 2 week wash-in period followed by 4 weeks of treatment with placebo or eplerenone. There will be a 2 week wash out period from study medications and then participants will take the other drug (placebo or eplerenone) for 4 weeks. In addition, participants will also provide urine and blood samples during the trial, have physical assessments, and be monitored for safety.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2021-01-12
• Study First Submitted QC: 2021-02-05
• Study First Posted: 2021-02-09
• Status Verified: 2023-02
• Study Start: 2023-02
• Last Update Submitted: 2023-02-16
• Last Update Posted: 2023-02-21
• Primary Completion: 2023-07-01
• Study Completion: 2023-12-01

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• History of mild stage 1 systemic hypertension as defined by:

  1. Systolic blood pressure (SBP) ≥ 140 millimeters of Mercury (mmHg) or diastolic blood pressure (DBP) ≥ 90 mmHg on 2 occasions and
  2. Treatment with 1-2 antihypertensive medications (stable dose for 6 weeks)

Read More

Exclusion Criteria

• Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
• Stage 2 hypertension (history of blood pressure ≥ 160/100 mmHg)
• History of hypertensive urgency, hypertensive crisis, or hospitalizations for hypertension
• Current mineralocorticoid antagonist use
• Type II Diabetes with microalbuminuria
• Primary adrenal insufficiency
• Current glucocorticoid use
• Electrolyte abnormality on baseline laboratory assessment
• Current potassium supplementation
• Positive test for leukocyte esterase on urinalysis
• Creatinine clearance < 50 mL/min on baseline laboratory assessment
• Hyperkalemia
• Potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene)
• Serum potassium >5.0 milliequivalents per liter (mEq/L) on baseline laboratory assessment
• Current use of strong CYP3A4 inhibitors (some include: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir).
• Serum creatinine > 1.5 mg/dL in males on baseline laboratory assessment
• Serum creatinine > 1.3 mg/dL in females
• Current beta blocker use
• Any other condition thought by the Principal Investigator to place the participant at increased risk of injury during the clinical trial or compromise the scientific integrity of the study

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Eplerenone	Eplerenone 50mg	Participants will be randomized to receive 4 weeks of Eplerenone and then 4 weeks of Placebo.
Placebo	Placebo	Participants will be randomized to receive 4 weeks of placebo and then 4 weeks of Eplerenone.

Primary Outcome Measures

Name	Time	Method
RT-qPCR Ct value of mineralocorticoid receptor-regulated gene mRNA	Week 12 (after second study treatment)	Cycle threshold of urinary mRNA biomarker following treatment with placebo and following treatment with eplerenone will be measured using RT-qPCR.
Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) Cycle threshold (Ct) value of mineralocorticoid receptor-regulated gene messenger ribonucleic acid (mRNA)	Week 6 (after first study treatment)	Cycle threshold of urinary mRNA biomarker following treatment with placebo and following treatment with eplerenone will be measured using RT-qPCR.

Trial Locations

Locations (1)

University of Michigan; 🇺🇸 Ann Arbor, Michigan, United States